 |
|
|
| |
Rational Design of Doravirine (DOR): A Review of Development From Bench to Patients
|
| |
| |
Reported by Jules Levin
IDWeek; San Francisco, CA; October 3-7, 2018
Carey Hwang, MD, PhD; Ming-Tain Lai, PhD; Daria Hazuda, PhD
Merck & Co., Inc., Kenilworth, NJ, USA
Merck has ongoing clinical study of 2-ART drug regimen combining doravirine with only long-acting MK8591 their new nuke-type of ART but different, and could also be a long-acting PrEP.
It has been recruiting & is ongoing:
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
New Long Acting Potent Nuke MK-8591 + Doravirine Phase 2B Study Starts
reported at IDWeek:
IDWeek: Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial - (10/06/18)
IDWeek: Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial - (10/06/18)
IDWeek: Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients - (10/06/18)
Poster pdf attached
Download the PDF here
|
| |
|
|
|
|
|
